Skip to main content
main-content

Free registration

Medicine Matters is developed for healthcare professionals as

a premier resource for the latest clinical information in medicine.

Editors' pick

03-04-2019 | Mental health | Editorial | Article

Diabetes and dementia: Addressing the needs of an overlooked population

Diabetologist Amar Puttanna addresses growing concerns about the rise of dementia in diabetes care and highlights where guidelines, research efforts, and management options are needed to tackle this comorbidity.

Hypoglycemia and technology

This 15-minute case presents the identification of problematic hypoglycemia and the appropriate use and monitoring of different technologies in the context of reducing the occurrence and risk of hypoglycemia.

03-18-2019 | Dapagliflozin | Highlight | News

DECLARE analyses show dapagliflozin benefits for reduced ejection fraction, prior MI subgroups

Further analysis of the DECLARE-TIMI 58 trial shows dapagliflozin to be of particular benefit for patients who have previous myocardial infarction or heart failure with reduced ejection fraction.

Conference coverage | Diabetes UK Professional Conference 2019

Visit the DUKPC conference hub for all of the coverage, including session reports, video interviews, and more.

Latest from across the site

03-22-2019 | Physical activity | News

HIIT plus resistance training may have cardiovascular benefits in type 2 diabetes

A 1-year exercise intervention combining high-intensity interval training with resistance training may improve measures of cardiovascular risk among people with type 2 diabetes, suggests a secondary analysis of the D2FIT trial.

03-21-2019 | Heart failure | News

Microvascular disease a marker of heart failure risk in type 2 diabetes

The presence of microvascular disease in people with type 2 diabetes signals a high risk for heart failure, report the EMPA-REG OUTCOME investigators.

03-20-2019 | Peripheral arterial disease | News

DECLARE-TIMI 58 outcomes consistent in people with peripheral artery disease

Patients with type 2 diabetes and peripheral artery disease may derive greater absolute benefit from dapagliflozin than those without the comorbidity due to their increased risk for cardiovascular and renal events, DECLARE-TIMI 58 data show.

03-19-2019 | Glycemic control | News

Benefits of full target monitoring shown in type 2 diabetes

Full monitoring of biomedical and lifestyle-related diabetes target indicators is associated with significantly lower glycated hemoglobin levels than incomplete monitoring among people with type 2 diabetes in a care group setting, say researchers.

03-18-2019 | Dapagliflozin | Highlight | News

DECLARE analyses show dapagliflozin benefits for reduced ejection fraction, prior MI subgroups

Further analysis of the DECLARE-TIMI 58 trial shows dapagliflozin to be of particular benefit for patients who have previous myocardial infarction or heart failure with reduced ejection fraction.

03-17-2019 | Canagliflozin | News

Canagliflozin may reduce HF events irrespective of ejection fraction

A post-hoc analysis of the CANVAS trial suggests that treatment with the sodium-glucose cotransporter 2 inhibitor canagliflozin reduces the risk for heart failure events regardless of whether patients have preserved or reduced ejection fraction.

Meet our Editorial Board

New Content Item Meet our Advisory Board

Latest from us on Twitter

Trending this week

image credits